Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.
Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.
复制标题
类风湿关节炎的管理：各种治疗方法的影响和风险。
DOI：
10.3892/etm.2016.3045
复制
发表时间：
2016-04
影响因子：
2.7
通讯作者：
Stan M
中科院分区：
文献类型：
--
作者：
Negrei C;Bojinca V;Balanescu A;Bojinca M;Baconi D;Spandidos DA;Tsatsakis AM;Stan M
风湿病是世界范围内非常普遍的慢性疾病，也是造成身体残疾的主要原因，具有显著的社会经济影响。类风湿性关节炎（RA）是一种病因不明的慢性全身性炎症性疾病，其自身免疫性发病机制以关节病变为特征，具有慢性、变形、破坏性演变和多种全身性表现。就目标和方法而言，RA的管理经历了重大变化，最终形成了目前被称为“从治疗到目标”的策略。类风湿性关节炎的治疗方法包括几种具有不同潜力的药品。用于治疗这种疾病的药品有几种分类标准，其中最重要和最现代的标准之一是根据对疾病进展的影响对这些物质进行分类：缓解症状的抗风湿药物（包括非甾体抗炎药和皮质激素），缓解疾病的抗风湿药物(包括各种物质，如金盐、抗疟药、磺胺吡啶、d -青霉胺；非特异性免疫抑制药物（如甲氨蝶呤、环磷酰胺、硫唑嘌呤和来氟米特）和生物治疗是最近增加的，为该疾病的治疗提供了新的见解。RA的最佳治疗方法的选择应基于指南和建议，但也应基于临床特殊方面和患者的偏好。
Rheumatic diseases are highly prevalent chronic disorders and the leading cause of physical disability worldwide, with a marked socio-economic impact. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology with an autoimmune pathogenesis, characterised by arthropathy with chronic, deforming, destructive evolution and multiple systemic manifestations. The management of RA has undergone significant changes as far as objectives and approaches are concerned, ending in the current strategy known as ‘treat to target’. The therapeutic array of RA includes several categories of medicinal products, of varying potential. There are several criteria for the classification of medicinal products used against this disease, one of the most important and modern of which divides such substances according to their effects on the progress of the disease: symptom-modifying antirheumatic drugs (including non-steroidal anti-inflammatory drugs and corticoids), disease-modifying antirheumatic drugs (including various substances, such as gold salts, antimalarials, sulfasalazine, D-penicillamine; non-specific immunosuppressive medication, such as methotrexate, cyclophosphamide, azathioprine and leflunomide) and biological therapy is a recent addition, providing new insight into the treatment of this disease. The selection of the optimal therapy for RA should be based on guidelines and recommendations, but also on clinical particular aspects and patient preferences.